Results 11 to 20 of about 140,447 (354)

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

Cancer Medicine
Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in ...
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani   +21 more
doaj   +2 more sources

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

New England Journal of Medicine, 2022
BACKGROUND Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however ...
P. Forde, J. Spicer, Shun Lu, M. Provencio, T. Mitsudomi, M. Awad, E. Felip, S. Broderick, J. Brahmer, S. Swanson, K. Kerr, Changli Wang, T. Ciuleanu, G. Saylors, F. Tanaka, H. Ito, Keke Chen, M. Liberman, E. Vokes, J. Taube, C. Dorange, Junliang Cai, J. Fiore, A. Jarkowski, D. Balli, M. Sausen, D. Pandya, C. Calvet, N. Girard   +28 more
semanticscholar   +1 more source

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

New England Journal of Medicine, 2022
BACKGROUND Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion.
H. Tawbi, D. Schadendorf, E. Lipson, P. Ascierto, L. Matamala, E. Castillo Gutiérrez, P. Rutkowski, H. Gogas, C. Lao, J. J. de Menezes, S. Dalle, A. Arance, J. Grob, Shivani Srivastava, Mena Abaskharoun, Melissa Hamilton, S. Keidel, K. Simonsen, A.M. Sobiesk, Bin Li, F. Hodi, G. Long   +21 more
semanticscholar   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2

IJU Case Reports, 2021
Introduction The efficacy of nivolumab for non‐clear cell renal cell carcinoma is still unclear. We present a rare case of metastatic papillary renal cell carcinoma remarkably responded to nivolumab but developed myeloradiculoneuropathy as immune‐related
Kazunori Iwasaki, Toshitaka Shin, Toru Inoue, Tadamasa Shibuya, Kenichi Hirai, Tadasuke Ando, Hiromitsu Mimata   +6 more
doaj   +1 more source

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

New England Journal of Medicine, 2021
BACKGROUND No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.
R. Kelly, J. Ajani, J. Kużdżał, T. Zander, E. Van Cutsem, G. Piessen, G. Mendez, J. Feliciano, S. Motoyama, A. Lièvre, H. Uronis, E. Elimova, C. Grootscholten, K. Geboes, S. Zafar, S. Snow, A. Ko, K. Feeney, M. Schenker, Piotr Kocoń, Jenny Zhang, Lili Zhu, M. Lei, Prianka Singh, K. Kondo, J. Cleary, M. Moehler   +26 more
semanticscholar   +1 more source

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

BMC Cancer, 2019
Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases.
Mark T. J. van Bussel, Jos H. Beijnen, Dieta Brandsma   +2 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

New England Journal of Medicine, 2019
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We randomly
J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, D. Hogg, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, L. Bastholt, J. Rizzo, Á. Balogh, A. Moshyk, F. Hodi, J. Wolchok   +30 more
semanticscholar   +1 more source

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

ESMO Open, 2019
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers.
Masahiko Aoki, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Kazuhide Higuchi, Narikazu Boku   +12 more
doaj   +1 more source